Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2013

View Archived Issues

Fumarate increased in ER-negative breast cancer in African American women

BB2 receptor expression elevated in low-grade PIN

Cancer Research Technology and AstraZeneca extend cancer metabolism alliance

RXi Pharmaceuticals and OPKO Health pool RNAi assets

OncoMed begins dosing in phase I trial of anti-Notch 1 antibody in solid tumors

Otsuka Pharmaceutical patents novel STEP inhibitors

Patrys reports additional data from phase I/IIa PAT-SM6 study

Acceleron begins new phase II trial to investigate ACE-536 in beta-thalassemia

Pernix Therapeutics completes acquisition

FDA advisory committee votes against salmon calcitonin use

Lpath and Provista Diagnostics collaborate to develop cancer diagnostics

CoCo Therapeutics founded to advance research findings in Alzheimer's disease

Qu Biologics commences phase I/II trial in Crohn's disease

Protalix gains approval to initiate study of oral treatment for Gaucher's disease in Israel

NeoStem to proceed with PreSERVE AMI phase II trial following second interim review

ITX-5061 proves safe, effective and virologically active following oral dosing

First in-human pharmacokinetic study for DA-0831

Korean researchers present clinical data for DP-R206 and ibandronate

HanAll BioPharma patents new AMPK inhibitors

Nippon Shinyaku patents novel MPGES-1 inhibitors

Researchers at Boehringer Ingelheim synthesize new sGC activators

Canadian team discloses new agents for cancer

Takeda seeks European approval of vedolizumab

Roche ends fibrosis alliance with Galapagos

Novel mutations in the ECM1 gene identified in siblings with lipoid proteinosis

APT imaging is able to differentiate high-grade brain tumors

Health Canada approves mirabegron